p62 Ligand Compounds for mTOR-Independent Aggregate Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for proteinopathies, such as neurodegenerative diseases, are ineffective in eliminating misfolded protein aggregates due to limitations in activating autophagy without affecting mTOR activity, and existing methods like mTOR inhibitors have broad impacts on cellular pathways.
Innovation Solution
Development of a novel p62 ligand compound that binds to the ZZ domain of p62, activating autophagy independently of mTOR, leading to the formation of p62 oligomers, increased binding to LC3, and delivery to autophagosomes for effective elimination of misfolded protein aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If mTOR inhibitors are used to activate autophagy, then autophagy activity is improved, but broad impacts on cellular pathways and lack of specificity occur
Solution Approach 1:
The patent introduces p62 as an intermediary molecule that specifically mediates selective autophagy. The p62 ligand compound binds to p62, which then acts as a bridge to recruit LC3 and deliver substrates to autophagosomes. This intermediary mechanism enables specific activation of selective autophagy without broadly affecting mTOR or other cellular pathways, resolving the contradiction between autophagy activation and specificity.
Solution Approach 2:
The patent segments the autophagy activation process into distinct components: a p62 ligand compound that binds to p62, p62 itself that binds to substrates and recruits LC3, and the autophagosome formation machinery. This segmentation allows selective activation of the p62-mediated autophagy pathway independent of mTOR, achieving both autophagy activation and pathway specificity.
2Productivity
If proteasome degradation is used to eliminate misfolded proteins, then protein degradation is improved, but aggregated proteins cannot be degraded due to narrow inner diameter
Solution Approach 1:
The patent uses p62 as an intermediary that binds to aggregated misfolded proteins and delivers them to autophagosomes. The p62 ligand compound enhances this intermediary function, enabling the autophagy system to handle aggregated proteins that the proteasome cannot process due to its narrow inner diameter constraint.
Solution Approach 2:
Instead of trying to force aggregated proteins through the narrow proteasome channel, the patent inverts the approach by using autophagy, which has a larger capacity to accommodate aggregated proteins. The p62 ligand compound facilitates this alternative degradation pathway, effectively bypassing the proteasome's size limitation.
3Productivity
If existing p62 ligand compounds with stereocenters are used, then autophagy activation is achieved, but racemic structures are employed reducing efficacy
Solution Approach 1:
The patent applies local quality by specifying the (R) configuration at the stereocenter in the p62 ligand compound. This local stereochemical specification optimizes the compound's binding affinity and activity toward p62, thereby enhancing autophagy activation efficacy compared to racemic mixtures.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.